Provectus Biopharmaceuticals (PVCT) 10-Q 14 May 24 2024 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2024	May 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-36457
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Entity Tax Identification Number	90-0031917
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	800 S. Gay Street
Entity Address, Address Line Two	Suite 1610
Entity Address, City or Town	Knoxville
Entity Address, State or Province	TN
Entity Address, Postal Zip Code	37929
City Area Code	866
Local Phone Number	594-5999
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		419,522,119
Entity Information, Former Legal or Registered Name	Not Applicable

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current Assets:
Cash	$ 18,035	$ 76,576
Restricted cash	744,717	950,223
Short-term receivables	98	476
Prepaid expenses and other current assets	245,954	337,522
Total Current Assets	1,008,804	1,364,797
Equipment and furnishings, less accumulated depreciation of $113,224 and $110,994, respectively	9,789	12,020
Operating lease right-of-use asset	60,398	72,026
Total Assets	1,078,991	1,448,843
Current Liabilities:
Accounts payable	1,369,957	1,675,891
Unearned grant revenue	715,176	953,248
Other accrued expenses	3,096,272	3,240,436
Notes payable	190,910	277,815
Operating lease liability, current portion	49,020	48,077
Total Current Liabilities	8,515,909	9,016,895
Operating lease liability, non-current portion	12,729	25,299
Total Liabilities	8,528,638	9,042,194
Commitments, contingencies, and litigations (Note 12)
Stockholders’ Deficit:
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 419,522,119 shares issued and outstanding at March 31, 2024 and December 31, 2023	419,522	419,522
Additional paid-in capital	245,362,902	244,714,967
Accumulated other comprehensive loss	(60,580)	(60,165)
Accumulated deficit	(253,194,451)	(252,690,409)
Total Stockholders’ Deficit	(7,449,647)	(7,593,351)
Total Liabilities and Stockholders’ Deficit	1,078,991	1,448,843
Series D Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	12,373	12,373
Series D-1 Convertible Preferred Stock [Member]
Stockholders’ Deficit:
Preferred stock, value	10,587	10,361
Nonrelated Party [Member]
Current Liabilities:
Accrued interest - related parties	40,660	22,600
Convertible notes payable - related parties	953,000	800,000
Related Party [Member]
Current Liabilities:
Accrued interest - related parties	110,914	123,828
Convertible notes payable - related parties	$ 1,990,000	$ 1,875,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accumulated depreciation, equipment and furnishings	$ 113,224	$ 110,994
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	419,522,119	419,522,119
Common stock, shares outstanding	419,522,119	419,522,119
Series D Convertible Preferred Stock [Member]
Preferred stock, shares authorized	12,374,000	12,374,000
Preferred stock, shares issued	12,373,247	12,373,247
Preferred stock, shares outstanding	12,373,247	12,373,247
Preferred stock, liquidation preference value	$ 14,164,889	$ 14,164,889
Series D-1 Convertible Preferred Stock [Member]
Preferred stock, shares authorized	11,241,000	11,241,000
Preferred stock, shares issued	10,587,571	10,361,097
Preferred stock, shares outstanding	10,587,571	10,361,097
Preferred stock, liquidation preference value	$ 121,205,780	$ 118,613,136

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Grant Revenue	$ 238,072	$ 205,025
Operating Expenses:
Research and development	555,535	548,393
General and administrative	129,802	438,845
Total Operating Expenses	685,337	987,238
Total Operating Loss	(447,265)	(782,213)
Other Expense:
Interest expense	(56,777)	(45,241)
Total Other Expense	(56,777)	(45,241)
Net Loss	$ (504,042)	$ (827,454)
Net Loss per share - basic	$ 0	$ 0
Net Loss per share - diluted	$ 0	$ 0
Weighted average number of shares - basic	419,522,119	419,497,119
Weighted average number of shares - diluted	419,522,119	419,497,119

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net Loss	$ (504,042)	$ (827,454)
Other Comprehensive (Loss)/Income:
Foreign currency translation adjustments	(415)	191
Total Comprehensive Loss	$ (504,457)	$ (827,263)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series D Preferred Stock [Member]	Preferred Stock [Member] Series D-1 Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022	$ 12,373	$ 9,747	$ 419,497	$ 242,954,193	$ (35,679)	$ (249,588,641)	$ (6,228,510)
Balance, shares at Dec. 31, 2022	12,373,247	9,746,626	419,497,119
Conversion of Note to Series D-1 Preferred Stock		$ 18		53,992			54,010
Conversion of Note to Series D-1 Preferred Stock, shares		18,872
Net loss						(827,454)	(827,454)
Other comprehensive income					191		191
Balance at Mar. 31, 2023	$ 12,373	$ 9,765	$ 419,497	243,008,185	(35,488)	(250,416,095)	(7,001,763)
Balance, shares at Mar. 31, 2023	12,373,247	9,765,498	419,497,119
Balance at Dec. 31, 2023	$ 12,373	$ 10,361	$ 419,522	244,714,967	(60,165)	(252,690,409)	(7,593,351)
Balance, shares at Dec. 31, 2023	12,373,247	10,361,097	419,522,119
Conversion of Note to Series D-1 Preferred Stock		$ 226		647,935			648,161
Conversion of Note to Series D-1 Preferred Stock, shares		226,474
Net loss						(504,042)	(504,042)
Other comprehensive income					(415)		(415)
Balance at Mar. 31, 2024	$ 12,373	$ 10,587	$ 419,522	$ 245,362,902	$ (60,580)	$ (253,194,451)	$ (7,449,647)
Balance, shares at Mar. 31, 2024	12,373,247	10,587,571	419,522,119

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities:
Net loss	$ (504,042)	$ (827,454)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash lease expense	11,628	11,069
Depreciation	2,231	2,230
Changes in operating assets and liabilities
Short term receivables	365	(393)
Prepaid expenses and other current assets	91,568	195,392
Accounts payable	(305,736)	(186,280)
Unearned grant revenue	(238,072)	(205,025)
Other accrued expenses	(144,118)	354,252
Operating lease liability	(11,627)	(10,730)
Accrued interest	53,308	42,829
Net Cash Used In Operating Activities	(1,044,495)	(624,110)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	153,000
Proceeds from issuance of convertible notes payable - related parties	815,000	600,000
Repayment of short-term note payable	(86,905)	(84,297)
Repayment of 2021 convertible note payable - related party	(100,000)
Net Cash Provided By Financing Activities	781,095	515,703
Effect of exchange rates on cash and restricted cash	(647)	(1,845)
Net Decrease In Cash and Restricted Cash	(264,047)	(110,252)
Cash and Restricted Cash, Beginning of Period	1,026,799	1,431,707
Cash and Restricted Cash, End of Period	762,752	1,321,455
Cash	18,035	34,153
Restricted cash	744,717	1,287,302
Supplemental Disclosures of Cash Flow Information:
Interest
Income taxes
Non-cash investing and financing activities:
Conversion of 2021 Notes and related accrued interest to Series D-1 Preferred Stock		54,010
Conversion of 2022 Notes and related accrued interest to Series D-1 Preferred Stock	$ 648,161

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	1. Business Organization, Nature of Operations and Basis of Presentation Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or “the Company”), is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (“HXs”). Our lead HX molecule is named rose bengal sodium (“RBS”). The Company’s proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug candidates of our current clinical development programs and the preclinical formulations of our current non-clinical early discovery programs. Importantly, our pharmaceutical-grade RBS displays different therapeutic effects at different concentrations and can be formulated for delivery by different routes of administration. The Company believes that RBS targets disease in a bifunctional manner. First, direct contact may lead to cell death or repair, depending on the disease being treated and the concentration of the RBS utilized in the treatment. Second, multivariate immune signaling, activation, and response may follow that may manifest as stimulatory, inhibitory, or both. The Company believes that it is the first entity to advance an RBS formulation into clinical trials for the treatment of a disease, such as those trials reported on the clinical trials registry at ClinicalTrials.gov. The Company believes that it is the first and only entity to date to make pharmaceutical-grade RBS successfully, reproducibly, and consistently at a purity of nearly 100%. The Company’s small molecule HX medical science platform comprises several different drug candidates and preclinical targets using different concentrations delivered by different routes of administration specific to each disease area and/or disease indication. The Company’s HX medical science platform includes clinical development programs in oncology (intratumoral administration), dermatology (topical), and ophthalmology (topical); in vivo in vitro Risks and Uncertainties The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2023 filed with the SEC on March 28, 2024. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s cash and restricted cash were $ 762,752 744,717 7,507,105 7,652,098 504,042 827,454 1,044,495 624,110 The Company plans to access capital resources through possible public or private equity offerings, including the 2022 financing (see Note 5), exchange offers, debt financings, corporate collaborations, or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although there can be no assurance that it will continue to be successful in the future. If the Company is unable to raise sufficient capital, it will not be able to pay its obligations as they become due. The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, there can be no assurance that it will be successful in co-developing, licensing, and/or commercializing PV-10, PH-10, and/or any other halogenated xanthene-based drug candidate developed by the Company or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2024 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, there can be no assurance that it will be able to obtain funds on commercially acceptable terms, or complete additional financing in a timely manner. Any such financing may result in significant dilution to stockholders. These factors raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of liabilities that may be necessary should we be unable to continue as a going concern. Our consolidated financial statements included elsewhere in this Annual Report on Form 10-K have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), which contemplate our continuation as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant Accounting Policies Since the date the Company’s December 31, 2023 consolidated financial statements were issued in its 2023 Annual Report on March 28, 2024, there have been no material changes to the Company’s significant accounting policies. Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets. Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of March 31, 2024 is $ 744,717 Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 512,752 776,799 Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2024 2023 March 31, 2024 2023 Warrants 412,500 475,000 Options 3,225,000 3,425,000 Convertible preferred stock 118,248,957 110,028,227 2021 unsecured convertible notes 494,041 3,860,043 2022 unsecured convertible notes 10,318,590 4,833,714 Total potentially dilutive shares 132,699,088 122,621,984 Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reporting segment are required to provide both the new disclosures and all of the existing disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023 In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for the Company for annual periods beginning after

Other Accrued Expenses

Other Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Other Accrued Expenses	4. Other Accrued Expenses The following table summarizes the other accrued expenses at March 31, 2024 and December 31, 2023: Schedule of Other Accrued Expenses 2024 2023 March 31, December 31, 2024 2023 Accrued payroll and taxes $ 827,432 $ 719,460 Accrued vacation 100,651 92,985 Accrued directors’ fees 1,976,839 2,330,589 Accrued other expenses 191,350 97,402 Total other accrued expenses $ 3,096,272 $ 3,240,436

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Convertible Notes Payable	5. Convertible Notes Payable The following summarizes convertible notes payable activity during the three months ended March 31, 2024: 2021 Financing Schedule of Convertible Notes Payable Non-Related Party Face Amount Related Party Face Amount Total Balance as of January 1, 2024 $ - $ 200,000 $ 200,000 Repayment - (100,000 ) (100,000 ) Balance as of March 31, 2024 $ - $ 100,000 $ 100,000 2022 Financing Non-Related Party Face Amount Related Party Face Amount Total Balance as of January 1, 2024 $ 800,000 $ 1,675,000 $ 2,475,000 Issued 153,000 815,000 968,000 Conversion - (600,000 ) (600,000 ) Balance as of March 31, 2024 $ 953,000 $ 1,890,000 $ 2,843,000 For further details on the terms of the 2021 and 2022 Notes, refer to our Form 10-K as filed with the SEC on March 28, 2024. 2024 Repayment of 2021 Notes During the three months ended March 31, 2024, the Company repaid $ 100,000 100,000 41,394 2024 Conversions of 2022 Notes into Preferred Stock During the three months ended March 31, 2024, principal and interest in the aggregate amount of $648,161 226,474 2.862

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable The Company obtained short-term financing from AFCO Insurance Premium Finance for our commercial insurance policies. As of March 31, 2024 and December 31, 2023, the balance of the note payable was $190,910 $277,815

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions During each of the three months ended March 31, 2024 and 2023, the Company had consulting fees of $ 63,600 250,000 258,000 500,000 $469,000 See Note 5 for details of other related party transactions. Director fees incurred during each of the three months ended March 31, 2024 and 2023 were $ 96,250 1,976,839 2,330,589

Stockholders_ Deficit

Stockholders’ Deficit	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Stockholders’ Deficit	8. Stockholders’ Deficit Preferred Stock During the three months ended March 31, 2024, the Company issued 226,474 $600,000 48,161 Options During the three months ended March 31, 2024 and 2023, the Company did not have any issuances, grants, or exercises of options. The following table summarizes option activities during the three months ended March 31, 2024: Schedule of Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Life in Years Aggregate Intrinsic Value Outstanding and exercisable at January 1, 2024 3,225,000 $ 0.27 $ - Forfeited - - Outstanding and exercisable at March 31, 2024 3,225,000 $ 0.27 1.62 $ - The following table summarizes information about options outstanding and exercisable at March 31, 2024: Summary of Stock Options Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.12 2,425,000 1.60 $ 152,775 $ 0.29 100,000 1.60 $ - $ 0.75 550,000 1.70 $ - $ 0.88 150,000 0.30 $ - 3,225,000 1.62 $ 152,775 Warrants During the three months ended March 31, 2024 and 2023, the Company did not have any issuances, grants, or exercises of warrants. The following table summarizes warrant activities during the nine months ended March 31, 2024: Schedule of Warrant Activity Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life in Years Aggregate Intrinsic Value Outstanding and exercisable at January 1, 2024 412,500 $ 1.07 Forfeited - - Outstanding and exercisable at March 31, 2024 412,500 $ 1.07 0.13 $ - The following table summarizes information about warrants outstanding and exercisable at March 31, 2024: Summary of Warrants Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.29 25,000 0.01 $ - $ 1.00 18,000 0.14 $ - $ 1.12 366,000 0.14 $ - $ 2.00 3,500 0.14 $ - 412,500 0.13 $ - Holders of the outstanding warrants are not entitled to vote and the exercise prices of such warrants are subject to customary anti-dilution provisions.

Leases

Leases	3 Months Ended
	Mar. 31, 2024
Leases
Leases	9. Leases On June 18, 2022, the Company leased 2,700 three years $4,053 $4,278 Total operating lease expense for the three months ended March 31, 2024 was $ 12,842 8,561 4,281 $13,507 $9,005 4,502 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Three Months Ended March 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 11,627 $ 10,730 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1 year 3 months 2 years 3 months Weighted Average Discount Rate Operating leases 5.0 % 5.0 8.0 % Future minimum payments under the Company’s non-cancellable lease obligations as of March 31, 2024 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2024 $ 38,166 2025 25,669 Total lease payments 63,835 Less: amount representing imputed interest (2,086 ) Present value of lease liability 61,749 Less: current portion (49,020 ) Lease liability, non-current portion $ 12,729

Grants

Grants	3 Months Ended
	Mar. 31, 2024
Grants
Grants	10. Grants On October 25, 2021, the Company received a grant award of $2,500,000 As of March 31, 2024 and December 31, 2023, $715,176 $953,248 $238,072 $205,025

License Transactions

License Transactions	3 Months Ended
	Mar. 31, 2024
License Transactions
License Transactions	11. License Transactions In the third quarter of 2019, the Company entered into a dialog with Bascom Palmer Eye Institute (“BPEI”) regarding collaboration on BPEI’s ophthalmic photodynamic antimicrobial therapy (“PDAT”) using the Company’s pharmaceutical-grade RBS. On February 16, 2022, and later amended on May 11, 2022, the Company entered into an option agreement with the University of Miami (“UM”) for an exclusive worldwide license of intellectual property (“IP”) developed by the Ophthalmic Biophysics Center (“OBC”) of BPEI that included the use of OBC’s PDAT medical device in combination with formulations of the Company’s pharmaceutical-grade RBS for the treatment of bacterial, fungal, and viral infections of the eye. The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis On March 21, 2024, the Company entered into an exclusive worldwide license for the IP. Details of the license agreement are reported in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 27, 2024.

Commitments, Contingencies and

Commitments, Contingencies and Litigation	3 Months Ended
	Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments, Contingencies and Litigation	12. Commitments, Contingencies and Litigation The Company may, from time to time, be involved in litigation arising from the ordinary course of business. The Company is not aware of any pending or threatened litigation that, if resolved against the Company, would have a material adverse effect on the Company’s condensed consolidated financial position, results of operations or cash flows.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	13. Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Convertible Notes Payable Subsequent to March 31, 2024, the Company entered into 2022 Notes with a related party investor (Executive Officer) in the aggregate principal amount of $ 95,000 Subsequent to March 31, 2024, the Company entered into 2022 Notes with a non-related party investor in the aggregate principal amount of $ 200,000 Series D-1 Preferred Stock Subsequent to March 31, 2024, principal and interest in the aggregate amount of $459,189 160,445 $2.862

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, accrued liabilities, and the valuation allowance related to the Company’s deferred tax assets.
Restricted Cash	Restricted Cash Restricted cash consists of a grant award received from the State of Tennessee. Restricted cash available as of March 31, 2024 is $ 744,717
Cash Concentrations	Cash Concentrations Cash and restricted cash are maintained at financial institutions and, at times, balances may exceed federally insured limits of $ 250,000 512,752 776,799
Basic and Diluted Loss Per Common Share	Basic and Diluted Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2024 2023 March 31, 2024 2023 Warrants 412,500 475,000 Options 3,225,000 3,425,000 Convertible preferred stock 118,248,957 110,028,227 2021 unsecured convertible notes 494,041 3,860,043 2022 unsecured convertible notes 10,318,590 4,833,714 Total potentially dilutive shares 132,699,088 122,621,984
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07 “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” These amendments require a public entity to disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. Public entities with a single reporting segment are required to provide both the new disclosures and all of the existing disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023 In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The amendments in this update address investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. This update also includes certain other amendments to improve the effectiveness of income tax disclosures. The amendments in ASU 2023-09 are effective for the Company for annual periods beginning after

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares	Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares 2024 2023 March 31, 2024 2023 Warrants 412,500 475,000 Options 3,225,000 3,425,000 Convertible preferred stock 118,248,957 110,028,227 2021 unsecured convertible notes 494,041 3,860,043 2022 unsecured convertible notes 10,318,590 4,833,714 Total potentially dilutive shares 132,699,088 122,621,984

Other Accrued Expenses (Tables)

Other Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
Schedule of Other Accrued Expenses	The following table summarizes the other accrued expenses at March 31, 2024 and December 31, 2023: Schedule of Other Accrued Expenses 2024 2023 March 31, December 31, 2024 2023 Accrued payroll and taxes $ 827,432 $ 719,460 Accrued vacation 100,651 92,985 Accrued directors’ fees 1,976,839 2,330,589 Accrued other expenses 191,350 97,402 Total other accrued expenses $ 3,096,272 $ 3,240,436

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Schedule of Convertible Notes Payable Non-Related Party Face Amount Related Party Face Amount Total Balance as of January 1, 2024 $ - $ 200,000 $ 200,000 Repayment - (100,000 ) (100,000 ) Balance as of March 31, 2024 $ - $ 100,000 $ 100,000 2022 Financing Non-Related Party Face Amount Related Party Face Amount Total Balance as of January 1, 2024 $ 800,000 $ 1,675,000 $ 2,475,000 Issued 153,000 815,000 968,000 Conversion - (600,000 ) (600,000 ) Balance as of March 31, 2024 $ 953,000 $ 1,890,000 $ 2,843,000

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	3 Months Ended
	Mar. 31, 2024
Equity [Abstract]
Schedule of Option Activity	The following table summarizes option activities during the three months ended March 31, 2024: Schedule of Option Activity Shares Weighted Average Exercise Price Weighted Average Remaining Life in Years Aggregate Intrinsic Value Outstanding and exercisable at January 1, 2024 3,225,000 $ 0.27 $ - Forfeited - - Outstanding and exercisable at March 31, 2024 3,225,000 $ 0.27 1.62 $ -
Summary of Stock Options Outstanding	The following table summarizes information about options outstanding and exercisable at March 31, 2024: Summary of Stock Options Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.12 2,425,000 1.60 $ 152,775 $ 0.29 100,000 1.60 $ - $ 0.75 550,000 1.70 $ - $ 0.88 150,000 0.30 $ - 3,225,000 1.62 $ 152,775
Schedule of Warrant Activity	The following table summarizes warrant activities during the nine months ended March 31, 2024: Schedule of Warrant Activity Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Life in Years Aggregate Intrinsic Value Outstanding and exercisable at January 1, 2024 412,500 $ 1.07 Forfeited - - Outstanding and exercisable at March 31, 2024 412,500 $ 1.07 0.13 $ -
Summary of Warrants Outstanding	The following table summarizes information about warrants outstanding and exercisable at March 31, 2024: Summary of Warrants Outstanding Exercise Price Outstanding and Exercisable Weighted Average Remaining Contractual Life Intrinsic Value $ 0.29 25,000 0.01 $ - $ 1.00 18,000 0.14 $ - $ 1.12 366,000 0.14 $ - $ 2.00 3,500 0.14 $ - 412,500 0.13 $ -

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Leases
Schedule of Right-of-use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right-of-use Assets and Liabilities For the Three Months Ended March 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases $ 11,627 $ 10,730 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 1 year 3 months 2 years 3 months Weighted Average Discount Rate Operating leases 5.0 % 5.0 8.0 %
Schedule of Future Minimum Payments Under Non-cancellable Lease	Future minimum payments under the Company’s non-cancellable lease obligations as of March 31, 2024 were as follows: Future Minimum Payments Schedule of Future Minimum Payments Under Non-cancellable Lease Years Amount 2024 $ 38,166 2025 25,669 Total lease payments 63,835 Less: amount representing imputed interest (2,086 ) Present value of lease liability 61,749 Less: current portion (49,020 ) Lease liability, non-current portion $ 12,729

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 762,752	$ 1,321,455	$ 1,026,799	$ 1,431,707
Restricted cash	744,717	1,287,302
Working capital deficiency	7,507,105		$ 7,652,098
Net loss	(504,042)	(827,454)
Net cash used in operations	$ 1,044,495	$ 624,110

Schedule of Securities Excluded

Schedule of Securities Excluded from Calculation of Weighted Average Dilutive Common Shares (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	132,699,088	122,621,984
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	412,500	475,000
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	3,225,000	3,425,000
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	118,248,957	110,028,227
2021 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	494,041	3,860,043
2022 Unsecured Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	10,318,590	4,833,714

Significant Accounting Polici_4

Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accounting Policies [Abstract]
Restricted cash	$ 744,717	$ 950,223
Insured limits	250,000
Cash in excess FDIC insured amount	$ 512,752	$ 776,799

Schedule of Other Accrued Expen

Schedule of Other Accrued Expenses (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accrued payroll and taxes	$ 827,432	$ 719,460
Accrued vacation	100,651	92,985
Accrued directors’ fees	1,976,839	2,330,589
Accrued other expenses	191,350	97,402
Total other accrued expenses	$ 3,096,272	$ 3,240,436

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
2021 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	$ 200,000
Repayment	(100,000)
Balance as of March 31, 2024	100,000
2021 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024
Repayment
Balance as of March 31, 2024
2021 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	200,000
Repayment	(100,000)
Balance as of March 31, 2024	100,000
2022 Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	2,475,000
Balance as of March 31, 2024	2,843,000
Issued	968,000
Conversion	(600,000)
2022 Convertible Notes Payable [Member] | Nonrelated Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	800,000
Balance as of March 31, 2024	953,000
Issued	153,000
Conversion
2022 Convertible Notes Payable [Member] | Related Party [Member]
Short-Term Debt [Line Items]
Balance as of January 1, 2024	1,675,000
Balance as of March 31, 2024	1,890,000
Issued	815,000
Conversion	$ (600,000)

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
2024 Repayments of 2021 Notes [Member]
Short-Term Debt [Line Items]
Repaid Principal	$ 100,000
Principal	100,000
Interest	41,394
2024 Conversions of 2022 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]
Short-Term Debt [Line Items]
Aggregate amount	$ 648,161
Number of shares | shares	226,474
Conversion price per share | $ / shares	$ 2.862

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Note payable	$ 190,910	$ 277,815

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			3 Months Ended
	Jun. 30, 2024	Mar. 26, 2024	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Related Party Transaction [Line Items]
Director fees			$ 96,250	$ 96,250
Accrued director fees			1,976,839		$ 2,330,589
Mr. Bruce Horowitz [Member]
Related Party Transaction [Line Items]
Consulting fees			63,600	$ 63,600
Mr Horowitz [Member]
Related Party Transaction [Line Items]
Payment of related party		$ 250,000
Director fees			$ 469,000
Mr Horowitz [Member] | Forecast [Member]
Related Party Transaction [Line Items]
Related party Balance due	$ 258,000
Mr Horowitz [Member] | Second Payment [Member]
Related Party Transaction [Line Items]
Payment of related party		$ 500,000

Schedule of Option Activity (De

Schedule of Option Activity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Number of options outstanding and exercisable, beginning balace | shares	3,225,000
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 0.27
Intrinsic Value, Outstanding | $
Stock options, forfeited | shares
Weighted average exercise price, forfeited | $ / shares
Number of options outstanding and exercisable, ending balance | shares	3,225,000
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares	$ 0.27
Weighted Average Remaining Contractual Life, Exercisable	1 year 7 months 13 days

Summary of Stock Options Outsta

Summary of Stock Options Outstanding (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.27	$ 0.27
Outstanding	3,225,000	3,225,000
Weighted Average Remaining Contractual Life, Exercisable	1 year 7 months 13 days
Intrinsic Value, Outstanding
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding	3,225,000
Exercisable	3,225,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 7 months 13 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 7 months 13 days
Intrinsic Value, Outstanding	$ 152,775
Intrinsic Value, Exercisable	$ 152,775
Range One [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.12
Exercise Price, Exercisable	$ 0.12
Outstanding	2,425,000
Exercisable	2,425,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 7 months 6 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 7 months 6 days
Intrinsic Value, Outstanding	$ 152,775
Intrinsic Value, Exercisable	$ 152,775
Range Two [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.29
Exercise Price, Exercisable	$ 0.29
Outstanding	100,000
Exercisable	100,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 7 months 6 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 7 months 6 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Three [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.75
Exercise Price, Exercisable	$ 0.75
Outstanding	550,000
Exercisable	550,000
Weighted Average Remaining Contractual Life, Outstanding	1 year 8 months 12 days
Weighted Average Remaining Contractual Life, Exercisable	1 year 8 months 12 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Four [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise Price, Outstanding	$ 0.88
Exercise Price, Exercisable	$ 0.88
Outstanding	150,000
Exercisable	150,000
Weighted Average Remaining Contractual Life, Outstanding	3 months 18 days
Weighted Average Remaining Contractual Life, Exercisable	3 months 18 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	3 Months Ended
	Mar. 31, 2024 USD ($) $ / shares shares
Equity [Abstract]
Warrants outstanding and exercisable, beginning balance | shares	412,500
Weighted average exercise price outstanding and exercisable, beginning balance | $ / shares	$ 1.07
Warrants, forfeited | shares
Weighted average exercise price, forfeited | $ / shares
Warrants outstanding and exercisable, ending balance | shares	412,500
Weighted average exercise price outstanding and exercisable, ending balance | $ / shares	$ 1.07
Weighted Average Remaining Contractual Life, Outstanding	1 month 17 days
Intrinsic Value | $

Summary of Warrants Outstanding

Summary of Warrants Outstanding (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding	412,500	412,500
Weighted Average Remaining Contractual Life, Outstanding	1 month 17 days
Intrinsic Value, Exercisable
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding	412,500
Exercisable	412,500
Weighted Average Remaining Contractual Life, Outstanding	1 month 17 days
Weighted Average Remaining Contractual Life, Exercisable	1 month 17 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 0.29
Exercise Price, Exercisable	$ 0.29
Outstanding	25,000
Exercisable	25,000
Weighted Average Remaining Contractual Life, Outstanding	3 days
Weighted Average Remaining Contractual Life, Exercisable	3 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Two [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 1
Exercise Price, Exercisable	$ 1
Outstanding	18,000
Exercisable	18,000
Weighted Average Remaining Contractual Life, Outstanding	1 month 20 days
Weighted Average Remaining Contractual Life, Exercisable	1 month 20 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Three [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 1.12
Exercise Price, Exercisable	$ 1.12
Outstanding	366,000
Exercisable	366,000
Weighted Average Remaining Contractual Life, Outstanding	1 month 20 days
Weighted Average Remaining Contractual Life, Exercisable	1 month 20 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable
Range Four [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise Price, Outstanding	$ 2
Exercise Price, Exercisable	$ 2
Outstanding	3,500
Exercisable	3,500
Weighted Average Remaining Contractual Life, Outstanding	1 month 20 days
Weighted Average Remaining Contractual Life, Exercisable	1 month 20 days
Intrinsic Value, Outstanding
Intrinsic Value, Exercisable

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative) - Series D-1 Convertible Preferred Stock [Member] - 2021 Notes [Member]	3 Months Ended
	Mar. 31, 2024 USD ($) shares
Class of Stock [Line Items]
Issuance of stock, shares | shares	226,474
Conversion of principal	$ 600,000
Conversion of accrued interest	$ 48,161

Schedule of Right-of-use Assets

Schedule of Right-of-use Assets and Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 11,627	$ 10,730
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	1 year 3 months	2 years 3 months
Weighted Average Discount Rate: Operating leases	5%
Minimum [Member]
Weighted Average Discount Rate: Operating leases		5%
Maximum [Member]
Weighted Average Discount Rate: Operating leases		8%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Leases
2024	$ 38,166
2025	25,669
Total lease payments	63,835
Less: amount representing imputed interest	(2,086)
Present value of lease liability	61,749
Less: current portion	(49,020)	$ (48,077)
Lease liability, non-current portion	$ 12,729	$ 25,299

Leases (Details Narrative)

Leases (Details Narrative)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jun. 18, 2022 ft²
Research and Development Expense [Member]
Operating lease, expense	$ 8,561	$ 9,005
General and Administrative Expense [Member]
Operating lease, expense	4,281	4,502
Property Subject to Operating Lease [Member]
Operating lease, expense	12,842	$ 13,507
Knoxville, Tennessee [Member]
Area of land | ft²			2,700
Lessee, operating lease, term of contract			3 years
Knoxville, Tennessee [Member] | Minimum [Member]
Rent expenses per month	4,053
Knoxville, Tennessee [Member] | Maximum [Member]
Rent expenses per month	$ 4,278

Grants (Details Narrative)

Grants (Details Narrative) - USD ($)		3 Months Ended
	Oct. 25, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Grants
Proceeds from grant	$ 2,500,000
Deferred revenue current		$ 715,176		$ 953,248
Revenue		$ 238,072	$ 205,025

License Transactions (Details N

License Transactions (Details Narrative)	3 Months Ended
	Mar. 31, 2024
License Transactions
License transaction description	The Company completed the arrangements of this collaboration during the third quarter of 2022, whereby the Company paid $5,000 for the option that expires on May 31, 2023; agreed to pay up to $10,000 of new UM patent expenses for this IP during the period of the option and up to $25,000 of past UM patent expenses for this IP; and entered into a sponsored research agreement with UM on September 16, 2022 to study the combination of OBC’s PDAT and TOP PV-305, a formulation of the Company’s pharmaceutical-grade RBS, for the treatment of infectious keratitis

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Apr. 01, 2024 USD ($) $ / shares shares
Subsequent Event [Line Items]
Principal amount	$ 95,000
Series D-1 Convertible Preferred Stock [Member] | 2022 Note [Member]
Subsequent Event [Line Items]
Conversion of principal and interest	$ 459,189
Number of preferred stock converted | shares	160,445
Conversion price | $ / shares	$ 2.862
Nonrelated Party [Member]
Subsequent Event [Line Items]
Principal amount	$ 200,000